Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

Regeneron (REGN) came out with quarterly earnings ... (s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements ...

For 2025, Regeneron reiterated its projection for research-and-development spending in a range between $5.56 billion and $5.795 billion. The company cut the top end of its forecasted range for 2025 ...

Before you invest in Regeneron Pharmaceuticals, Inc. (REGN), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

Stories of personal connection to their work weren’t uncommon at the UB RENEW Institute’s spring poster session and ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc ... of seven analysts surveyed by Zacks Investment Research was for earnings of $8.43 per share.